Showing 4741-4750 of 10098 results for "".
- FDA Advisory Arm Backs XELJANZ for PsAhttps://practicaldermatology.com/news/fda-advisory-arm-backs-xeljanz-for-psa/2458098/The United States Food and Drug Administration’s (FDA) Arthritis Advisory Committee recommends the approval of Pfizer's XELJANZ® (tofacitinib) for the treatment of adults with active psoriatic arthritis (PsA). The Arthritis Advisory Commit
- DFD-29 Shows No Major impact on Healthy Microbial Flora in Rosaceahttps://practicaldermatology.com/news/dfd-29-shows-no-major-impact-on-healthy-microbial-flora-in-rosacea/2461785/DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) doesn’t disrupt the microbial floral in healthy adults with papulopustular rosacea, according to data from a Phase 1 clinical trial. DFD-29 is being developed for the treatment of papulopustular ros
- Update: Two More Payers to Cover DermTech’s Melanoma Testhttps://practicaldermatology.com/news/update-two-more-payers-to-cover-dermtechs-melanoma-test/2461514/Two new payers plan to cover the DermTech Melanoma Test, making the foundational assay available to approximately 1.2 million more people. The new insurers are Blues plan in Hawaii and a physician-founded, member-focused and community-based not-for-profit health plan in New York. T
- Galderma Launches Twyneo in the UShttps://practicaldermatology.com/news/galderma-launches-twyneo-in-the-us/2461128/Galderma has launched Twyneo (tretinoin and benzoyl peroxide) Cream, 0.1%/3% in the US. The launch takes place during the annual meeting of the American Academy of Dermatology (AAD) Annual Meeting. Twyneo Cream features patented microencapsulation technology t
- Coverage Decision May Jeopardize Image-guided Skin Cancer Treatment: Reporthttps://practicaldermatology.com/news/medicare-contractors-threaten-coverage-of-noninvasive-skin-cancer-treatment/2475193/Medicare Administrative Contractors (MACs) are proposing to withdraw insurance coverage for image-guided superficial radiation therapy (IGSRT), according to a news letter from SkinCure Oncology. IGSRT is an FDA-cleared, nonin
- Study: Belly Fat More Predictive of Psoriasis Than Overall Body Fathttps://practicaldermatology.com/news/study-belly-fat-more-predictive-of-psoriasis-than-overall-body-fat/2475108/Central adiposity—particularly abdominal fat—is more strongly linked to psoriasis risk than overall body fat, according to a new analysis published in the Journal of Investigative Dermatology.
- Study: Lotion Shows Efficacy in Treating Hyperkeratotic Plaque Psoriasishttps://practicaldermatology.com/news/hptaz-lotion-shows-efficacy-in-treating-hyperkeratotic-plaque-psoriasis/2475106/HP/TAZ lotion significantly improved hyperkeratotic psoriatic plaques in subgroups, according to recent data from a post hoc analysis of phase 3 trials. The authors of the post hoc analysis pooled data from two eight-week, v
- Analysis: PBoNT/A and ABoNT/A Show Fastest Onset in Glabellar Line Treatmenthttps://practicaldermatology.com/news/prabotulinum-toxin-a-demonstrates-sustained-efficacy-at-day-180/2474898/A newly published study reports the comparative effects of four botulinum toxin A (BoNT/A) formulations on glabellar strain, with observed differences in onset, longevity, and muscular strain patterns. Researchers publishing
- Zasocitinib Effective in TYK2 Inhibition for Inflammatory Skin Disease: Studyhttps://practicaldermatology.com/news/zasocitinib-effecgive-in-tyk2-inhibition-for-inflammatory-skin-disease/2474891/Zasocitinib, billed as a 'next-generation' therapy, showed pharmacologic potency and high specificity compared to Janus and other kinase inhibitors, according to new results published in the Journal of Investigative Dermatology</
- EFFISAYIL 2: Spesolimab Associated with Long-Term GPP Reliefhttps://practicaldermatology.com/news/effisayil-2-spesolimab-associated-with-long-term-gpp-relief/2474835/Patients with generalized pustular psoriasis (GPP) experienced sustained symptom control and quality of life (QoL) improvements when treated with spesolimab, according to an analysis of results from the EFFISAYIL 2 trial. Re